Raphael Pharmaceutical Inc. (RAPH)

Market Cap	28.25M
Revenue (ttm)	n/a
Net Income	-1.40M
EPS	-0.07
Shares Out	20.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111
Average Volume	516
Open	1.400
Previous Close	1.400
Day's Range	1.400 - 1.400
52-Week Range	0.040 - 1.400
Beta	2.70
RSI	53.39
Earnings Date	Mar 27, 2026

About Raphael Pharmaceutical

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. The company is headquartered in Tel Aviv-Jaffa, Israel.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Shlomo Pilo
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: RAPH